Lupus & antiphospholipid syndrome
Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus
Authors' conclusion
We demonstrated the significance of IL-4 in reversing B cell anergy and established the scientific rationale to treat SLE via blocking IL-4 signalling, also providing diagnostic and prognostic biomarkers to identify patients who are most likely going to benefit from such treatments.
Study context
- Population
- Healthy donors and patients with systemic lupus erythematosus (SLE); isolated naïve B cells from human peripheral blood
- Comparison
- Patients with SLE vs healthy donors
Methodological detailstranscriptome and B cell receptor (BCR) repertoire profiling, single-cell, in vitro
- Transcriptome and BCR repertoire profiling
- Single-cell
- In vitro
Main finding
As reported in the abstract
- Decrease and disruption of BND cells in SLE patients
- IL-4 an important cytokine driving these pathological changes
- IL-4 reversed B cell anergy by promoting BCR recycling to the cell surface via STAT6 signalling
Original publication
Interleukin 4-driven reversal of self-reactive B cell anergy contributes to the pathogenesis of systemic lupus erythematosus. Ann Rheum Dis. Published 11 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →